JACC:心室早搏相关性心肌病的病理生理研究

2018-12-15 MedSci MedSci原创

心室早搏(PVC)相关心肌病的病理生理机制尚不明确。本研究的目的旨在通过心律失常猪模型探究心肌病的发病机制。本研究对35例猪进行了起搏器的植入,其中一组于右心尖接受了长达14周的二联律起搏(RVA PVC; n = 10),一组于右心尖接受了规律140下/min的起搏刺激(RVA-140; n = 10),5例为对照。为了检测异位搏动不同步的作用,又进一步分组,一组与右室游离壁接受了长达12周的二

心室早搏(PVC)相关心肌病的病理生理机制尚不明确。本研究的目的旨在通过心律失常猪模型探究心肌病的发病机制。

本研究对35例猪进行了起搏器的植入,其中一组于右心尖接受了长达14周的二联律起搏(RVA PVC; n = 10),一组于右心尖接受了规律140下/min的起搏刺激(RVA-140; n = 10),5例为对照。为了检测异位搏动不同步的作用,又进一步分组,一组与右室游离壁接受了长达12周的二联律起搏(RVFW PVC; n = 5),一组于左室心外膜(LV Epi PVC; n = 5),一组于右心房(n=5)。14周后,RVA PVC组的左室射血分数明显低于RVA-140组和对照组(p < 0.05),左室射血分数降低幅度最大的是LV Epi PVC (65.2 ± 2.4% to 39.7 ± 3.0%; p < 0.01) 和RVFW PVC (66.1 ± 2.6% to 48.6 ± 2.7%; p < 0.01)。pRyR2, NCX-1, CaMKII-α和PLN蛋白水平在 LV Epi PVC组中明显增高,SERCA2a 蛋白水平明显下降(p < 0.05)。另外,异位搏动QRS持续时间越长和左室不同步程度越大与左室收缩功能下降越大呈相关性。

研究结果显示,在猪模型中,心室早搏引起的心肌病表现与心动过速引起的心肌病不一样,心肌病的严重程度与血流动力学紊乱程度呈相关性。

原始出处:

本文系梅斯医学(MedSci)原创编译整理,转载需授权

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1837611, encodeId=9ba4183e61118, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jun 15 19:03:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701774, encodeId=53bc1e01774cd, content=<a href='/topic/show?id=9c35e104573' target=_blank style='color:#2F92EE;'>#病理生理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71045, encryptionId=9c35e104573, topicName=病理生理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d59730392519, createdName=许安, createdTime=Tue Feb 26 05:03:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854253, encodeId=ff8918542531b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Nov 13 16:03:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326066, encodeId=b958132606627, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Dec 17 09:03:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521418, encodeId=712d1521418d4, content=<a href='/topic/show?id=eee459319c0' target=_blank style='color:#2F92EE;'>#早搏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59319, encryptionId=eee459319c0, topicName=早搏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1f611339865, createdName=bioon7, createdTime=Mon Dec 17 09:03:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622364, encodeId=3230162236444, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Dec 17 09:03:00 CST 2018, time=2018-12-17, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1837611, encodeId=9ba4183e61118, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jun 15 19:03:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701774, encodeId=53bc1e01774cd, content=<a href='/topic/show?id=9c35e104573' target=_blank style='color:#2F92EE;'>#病理生理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71045, encryptionId=9c35e104573, topicName=病理生理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d59730392519, createdName=许安, createdTime=Tue Feb 26 05:03:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854253, encodeId=ff8918542531b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Nov 13 16:03:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326066, encodeId=b958132606627, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Dec 17 09:03:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521418, encodeId=712d1521418d4, content=<a href='/topic/show?id=eee459319c0' target=_blank style='color:#2F92EE;'>#早搏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59319, encryptionId=eee459319c0, topicName=早搏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1f611339865, createdName=bioon7, createdTime=Mon Dec 17 09:03:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622364, encodeId=3230162236444, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Dec 17 09:03:00 CST 2018, time=2018-12-17, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1837611, encodeId=9ba4183e61118, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jun 15 19:03:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701774, encodeId=53bc1e01774cd, content=<a href='/topic/show?id=9c35e104573' target=_blank style='color:#2F92EE;'>#病理生理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71045, encryptionId=9c35e104573, topicName=病理生理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d59730392519, createdName=许安, createdTime=Tue Feb 26 05:03:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854253, encodeId=ff8918542531b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Nov 13 16:03:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326066, encodeId=b958132606627, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Dec 17 09:03:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521418, encodeId=712d1521418d4, content=<a href='/topic/show?id=eee459319c0' target=_blank style='color:#2F92EE;'>#早搏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59319, encryptionId=eee459319c0, topicName=早搏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1f611339865, createdName=bioon7, createdTime=Mon Dec 17 09:03:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622364, encodeId=3230162236444, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Dec 17 09:03:00 CST 2018, time=2018-12-17, status=1, ipAttribution=)]
    2019-11-13 hbwxf
  4. [GetPortalCommentsPageByObjectIdResponse(id=1837611, encodeId=9ba4183e61118, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jun 15 19:03:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701774, encodeId=53bc1e01774cd, content=<a href='/topic/show?id=9c35e104573' target=_blank style='color:#2F92EE;'>#病理生理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71045, encryptionId=9c35e104573, topicName=病理生理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d59730392519, createdName=许安, createdTime=Tue Feb 26 05:03:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854253, encodeId=ff8918542531b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Nov 13 16:03:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326066, encodeId=b958132606627, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Dec 17 09:03:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521418, encodeId=712d1521418d4, content=<a href='/topic/show?id=eee459319c0' target=_blank style='color:#2F92EE;'>#早搏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59319, encryptionId=eee459319c0, topicName=早搏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1f611339865, createdName=bioon7, createdTime=Mon Dec 17 09:03:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622364, encodeId=3230162236444, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Dec 17 09:03:00 CST 2018, time=2018-12-17, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1837611, encodeId=9ba4183e61118, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jun 15 19:03:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701774, encodeId=53bc1e01774cd, content=<a href='/topic/show?id=9c35e104573' target=_blank style='color:#2F92EE;'>#病理生理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71045, encryptionId=9c35e104573, topicName=病理生理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d59730392519, createdName=许安, createdTime=Tue Feb 26 05:03:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854253, encodeId=ff8918542531b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Nov 13 16:03:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326066, encodeId=b958132606627, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Dec 17 09:03:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521418, encodeId=712d1521418d4, content=<a href='/topic/show?id=eee459319c0' target=_blank style='color:#2F92EE;'>#早搏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59319, encryptionId=eee459319c0, topicName=早搏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1f611339865, createdName=bioon7, createdTime=Mon Dec 17 09:03:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622364, encodeId=3230162236444, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Dec 17 09:03:00 CST 2018, time=2018-12-17, status=1, ipAttribution=)]
    2018-12-17 bioon7
  6. [GetPortalCommentsPageByObjectIdResponse(id=1837611, encodeId=9ba4183e61118, content=<a href='/topic/show?id=3f34e253206' target=_blank style='color:#2F92EE;'>#相关性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72532, encryptionId=3f34e253206, topicName=相关性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a9de34, createdName=shenxlcyp, createdTime=Sat Jun 15 19:03:00 CST 2019, time=2019-06-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1701774, encodeId=53bc1e01774cd, content=<a href='/topic/show?id=9c35e104573' target=_blank style='color:#2F92EE;'>#病理生理#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=71045, encryptionId=9c35e104573, topicName=病理生理)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=d59730392519, createdName=许安, createdTime=Tue Feb 26 05:03:00 CST 2019, time=2019-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1854253, encodeId=ff8918542531b, content=<a href='/topic/show?id=48351020537' target=_blank style='color:#2F92EE;'>#JACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10205, encryptionId=48351020537, topicName=JACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=55ce62, createdName=hbwxf, createdTime=Wed Nov 13 16:03:00 CST 2019, time=2019-11-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1326066, encodeId=b958132606627, content=<a href='/topic/show?id=96c71804b7' target=_blank style='color:#2F92EE;'>#ACC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1804, encryptionId=96c71804b7, topicName=ACC)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1e452500029, createdName=12498568m50暂无昵称, createdTime=Mon Dec 17 09:03:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1521418, encodeId=712d1521418d4, content=<a href='/topic/show?id=eee459319c0' target=_blank style='color:#2F92EE;'>#早搏#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59319, encryptionId=eee459319c0, topicName=早搏)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a1f611339865, createdName=bioon7, createdTime=Mon Dec 17 09:03:00 CST 2018, time=2018-12-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1622364, encodeId=3230162236444, content=<a href='/topic/show?id=b9578094833' target=_blank style='color:#2F92EE;'>#肌病#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80948, encryptionId=b9578094833, topicName=肌病)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=395f25, createdName=爆笑小医, createdTime=Mon Dec 17 09:03:00 CST 2018, time=2018-12-17, status=1, ipAttribution=)]

相关资讯

JACC:一种新型的自膨式可复位心脏瓣膜

新型自膨式可复位的经导管心脏瓣膜(THV)系统是被设计用于治疗严重的有临床症状且外科风险的主动脉瓣狭窄患者。本研究的目的旨在评估该新型THV系统的1年疗效。本次多中心临床试验是用于评估植入该新型THV后30天、1年和5年的预后,主要终点事件是术后1年的全因死亡率,次要终点事件是临床预后和心超指标。最终共纳入941名患者(82.4 ± 5.9岁,女性占65.7%),术后1年,全因死亡率、心血管死亡率

Lancet Diabetes Endocrinol:糖尿病药物利拉鲁肽或能有效降低患者心血管疾病事件的风险

利拉鲁肽的使用还与患者心血管疾病死亡风险降低以及任何原因导致的死亡风险降低直接相关,在亚群分析中,研究者指出,有心血管疾病史的患者似乎会因利拉鲁肽疗法而获益,尽管其与无疾病史患者之间并无统计学意义。最后研究者Bjorn Pasternak说道,本文研究表明,药物利拉鲁肽在更广泛的未选择的患者群体中能带来心血管健康的益处,同时还能提供重要的临床验证证据。

Circulation:心血管疾病治疗 请拥抱人工智能!

人工智能技术不断发展,正在加速向医疗领域渗透融合。2018年11月,发表在《Circulation》的一篇综述,概述了人工智能平台如何改善心血管疾病患者的医疗服务。

Circ-Heart Fail:心力衰竭患者甲状腺功能障碍与心血管结局

在既往心力衰竭的患者中,TSH≥7mIU/L的亚临床甲状腺功能减退症和单纯性低T3水平与预后不良有关。需要临床试验来探讨接受T4和T3治疗在心力衰竭中的治疗效果。

JACC:SYNTAX 评分在糖尿病伴复杂冠心病患者中的应用

糖尿病(DM)与复杂型冠心病的发生相关,从而增加了心血管并发症的发病率和死亡率。本研究的目的旨在通过SYNTAX 评分(SS)预测接受冠脉搭桥(CABG)或经皮冠脉介入治疗(PCI)的糖尿病伴复杂冠心病患者的心血管预后。本研究纳入分析了FREEDOM 临床试验中的患者,硬性心血管终点事件(HCE)为全因死亡、非致死性心梗和非致死性卒中的复合事件,主要不良心脑血管事件(MACCE)为HCE和反复性血

J Diabetes Investig:代谢综合征增加糖尿病前期患者心血管风险

一项最新研究结果显示,在中国成人糖尿病前期患者中,代谢综合征使主要心血管事件发生风险增加。